Teratogenicity Data for COVID Pill Already Submitted to Japan Regulators: Shionogi

Following media reports that the risk of birth defects was identified for its COVID-19 pill, Shionogi issued a statement on April 13 stressing that the company has already submitted its non-clinical teratogenicity data to Japanese regulators for review. According to...read more